EPIRUS Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development, manufacturing and commercialization of biosimilar therapeutics. The Company�s pipeline of biosimilar product candidates includes BOW015, a biosimilar version of infliximab;BOW050, a biosimilar version of Humira (adalimumab), and BOW070, a biosimilar version of Actemra (tocilizumab). BOW050 (Adalimumab) and BOW070 (Tocilizumab) are in the preclinical stage of development. The Company�s lead product candidate is BOW015, which is indicated for the treatment of various inflammatory diseases, including rheumatoid arthritis, Crohn's Disease, ankylosing spondylitis, psoriatic arthritis and psoriasis.